Navigation Links
New key element discovered in pathogenesis of Burkitt lymphoma
Date:8/13/2012

Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine Sander and Professor Klaus Rajewsky of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch have identified a key element that transforms the immune cells into malignant lymphoma cells. They developed a mouse model that closely resembles Burkitt lymphoma in humans and that may help to test new treatment strategies (Cancer Cell)*.

Burkitt lymphoma typically develops in childhood and occurs most frequently in equatorial Africa and South America. This tumor originates from germinal centers of the lymphoid organs (Peyer's patches in the small intestine, lymph nodes and spleen). The germinal center reaction is initiated by mature B cells upon detection of a foreign substance (antigen). These B cells modify their DNA in the course of the reaction, resulting finally in a highly specific antibody response against the antigen.

The B cell receptor (BCR), an antibody presented on the surface of mature B cells, plays a crucial role in the germinal center reaction. In order to optimally recognize the respective antigen and initiate an appropriate immune response, the DNA segments encoding the antibody need to be modified and rearranged. While the processes are complex, DNA breaks occur and error-prone repair mechanisms may lead to genetic mutations associated with cancer development.

It is well established that in Burkitt lymphoma, mistakes in the repair of DNA breaks result in the translocation of the c-MYC oncogene. This gene regulates cell division, and thus its expression is tightly controlled in normal cells. The c-MYC translocation leads to its deregulation, and the affected cells divide in an uncontrolled manner. However, c-MYC overexpression also leads to massive cell death. Therefore c-MYC deregulation by itself is unable to transform normal cells into cancer cells. In Burkitt lymphoma, the apoptosis induction of elevated c-MYC expression must be overcome by additional mutations preventing cell death.

Recently, Professor Rajewsky and his colleagues showed that an enzyme called PI3K is critical for the survival of mature B cells. It activates a signaling pathway that regulates cell growth and counteracts programmed cell death. Based on these findings Dr. Sander and Professor Rajewsky investigated an interaction of c-MYC and PI3K in mouse tumorigenesis in their present study. They demonstrated that PI3K is a key element in Burkitt lymphoma development which enables c-MYC to turn germinal center B lymphocytes into lymphoma cells that divide continuously and escape apoptosis.

However, not every B cell co-expressing c-MYC and PI3K transforms into a lymphoma cell, thus the researchers suspected additional genetic mutations that may play a role in Burkitt lymphomagenesis. Indeed they could identify such aberrations in their mouse model, and a study in human Burkitt lymphoma by Professor Louis Staudt (National Cancer Institute, Bethesda, Maryland, USA), which was published simultaneously in Nature (DOI: 10.1038/nature11378), confirmed these results. Staudt and colleagues showed that Burkitt lymphoma patients, besides having mutations resulting in the activation of the PI3K signaling pathway, carry genetic mutations that resemble those in the mouse.

"In addition to c-MYC deregulation, the activation of the PI3K signaling pathway is a key element in the development of Burkitt lymphoma," said Dr. Sander and Professor Rajewsky. "The inhibition of this signaling pathway could therefore be an effective strategy for treating the disease."


'/>"/>

Contact: bachtler@mdc-berlin.de
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. First direct evidence that elemental fluorine occurs in nature
2. Unexpected crustacean diversity discovered in northern freshwater ecosystems
3. University of Alberta led research may have discovered how memories are encoded in our brains
4. Newly discovered foot points to a new kid on the hominin block
5. New immune defense enzyme discovered
6. New genetic mechanism of immune deficiency discovered
7. Housekeeping mechanism for brain stem cells discovered
8. Scientists have discovered genes that increase the risk of osteoporosis and fractures
9. New form of intellectual disability discovered
10. 24 new species of lizards discovered on Caribbean islands are close to extinction
11. Key proteins newly discovered form and function may provide novel cancer treatment target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 28, 2017   Acuant , a leading provider ... significant enhancements to new and core technologies building upon ... include mobile and desktop Acuant FRM TM facial ... a real time manual review of identity documents by ... the fastest and most accurate capture software to streamline ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring ... of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. ... activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals and ...
(Date:3/22/2017)... , March 22, 2017 Good Start ... it has eclipsed the 130 million covered lives mark ... Shield of Texas . With newly ... Company continues to enjoy strong payor acceptance based on ... clinical programs and genetic counseling, its industry-leading customer care ...
(Date:3/22/2017)... 2017 /PRNewswire/ - FACIT announced a seed stage ... a start-up created by FACIT focused on developing ... combined with non-dilutive capital, achieves a targeted $3.0M ... enables Propellon to accelerate the nomination of a ... and/or entering a strategic partnership for clinical trials ...
(Date:3/22/2017)... Linda, Ca (PRWEB) , ... March 21, 2017 ... ... and clearance of biologics. To acquire information on the desired increase and/or decrease ... the biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , To ...
Breaking Biology Technology: